Home » Topics » BioWorld Science

BioWorld Science
RSS

EMA committee recommends marketing authorization for Veyvondi

July 2, 2018

IMpassion130 study of Tecentriq plus Abraxane meets primary endpoint

July 2, 2018

Lynparza receives Japanese approval for BRCA-mutated metastatic breast cancer

July 2, 2018

CHMP adopts positive opinion for Yescarta

July 2, 2018

Phase II results presented from pivotal CAPTIVATE trial of ibrutinib plus venetoclax

July 2, 2018

Refixia obtain Japanese approval for the treatment of hemophilia B

July 2, 2018

Kymriah granted positive CHMP opinion for the treatment of two aggressive blood cancers

July 2, 2018

Patient enrollment ongoing in phase I/II study of SOBI-003 in pediatric MPS IIIA

July 2, 2018

First-in-human study of D-0502 is enrolling participants

July 2, 2018

Ocular Therapeutix announces NDA resubmission to the FDA for Dextenza

July 2, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.